Semaglutide’s patent expiry has triggered global divergence, with India seeing rapid generic entry and price cuts, China promoting innovation, and the US maintaining exclusivity, forcing Novo Nordisk to adapt its strategy across sharply contrasting regulatory and market landscapes.
The March 20, 2026 expiration of the "molecule patent" for semaglutide is fast becoming a defining moment for the global pharmaceutical industry, exposing stark contrasts in how major markets handle the loss of exclusivity.What began as a routine patent expiry has triggered a "floodgate" effect in some jurisdictions, unleashing waves of generics and aggressive price competition, while others continue to shield the drug through layered protections and regulatory frameworks.
At the center of this shift is Novo Nordisk, which built a multibillion-dollar franchise on semaglutide’s dual promise in diabetes and weight loss — and is now being forced to recalibrate its strategy across sharply diverging markets.
Nowhere is that reset more visible than in India. As a wave of domestic generics enters the market, Novo — long protected by the blockbuster drug’s patent — has abandoned premium pricing to defend its position. The drug, widely used for blood-sugar control and increasingly for weight loss, is now at the center of an intense affordability battle.
In a sharp strategic pivot, Novo has cut prices by nearly 50 percent for its flagship treatments, signalling that the contest for India’s vast diabetic and obese population will be won on price, not just brand legacy.
Novo Nordisk India managing director Vikrant Shrotriya said the move is aimed "to make best-in-class cardiometabolic care more affordable for as many people with type 2 diabetes, overweight and obesity in India as possible." With India facing a massive burden of metabolic disease, the company is positioning its portfolio as both effective and scalable, he added.
The story is no longer merely about intellectual property; it is a scramble for market share in a rapidly expanding market. Novo estimates 101 million people in India live with diabetes and 254 million with obesity — a public health crisis driving both demand and costs.
Novo is betting that aggressive price cuts — including a 48 percent reduction for the starting dose of Wegovy — will blunt generic competition. By trading margins for volume, it aims to remain the default choice in a price-sensitive market.
— Trust v pricing —
Efficacy remains the central hurdle for semaglutide generics.
Novo’s brand strength continues to anchor physician and patient confidence. “Ozempic has proven efficacy and trust amongst doctors and patients. Generic drugs with different formulation have yet to earn that trust... only time will test how efficacious the generics are,” Mamta Jha, co-managing partner at Inttl Advocare representing Novo, told MLex.
While companies such as Torrent Pharmaceuticals and Dr. Reddy’s Laboratories argue their versions fall "outside the range" of Novo’s patent for the oral formulation Rybelsus, those claims remain untested in court.
"Generic drugs with different formulations are yet to earn that trust for their products," particularly given the strict cold-chain requirements, Jha said.
Only time will determine whether generics can match the originator’s performance, she added, citing Novartis’ Glivec — whose sales grew even after patent expiry due to entrenched clinical confidence.
Still, the competitive threat is real. The biggest challenge for Novo will come "from established Indian giants like Dr. Reddy’s, which already have considerable brand presence in India," said Ashneet Hanspal of Ahlawat & Associates.
"Only established manufacturers would be able to sustain the cost of production and distribution, which require sophisticated technology...in compliance with regulatory standards," Hanspal said, adding that India’s drug regulator, the Central Drugs Standard Control Organization, recently announced its intent to tighten oversight of this drug category.
— Brand vs. trademark —
With the primary patent gone, the battleground has shifted from science to branding.
Analysts expect 40 to 50 generics to enter India’s market, including products from Dr. Reddy's, Sun Pharma, Cipla, Lupin and Zydus — many priced 70 to 90 percent lower than the original price of Novo's patented drugs.
Dr. Reddy’s, among the first movers, quickly found itself in a legal "phonetic trap."
Seeking to leverage Novo’s brand recall, it launched a product under the name "Olymviq," prompting a swift injunction from the Delhi High Court over its similarity to "Ozempic" (see here).
Following the Cadila Healthcare principle, “courts have noted that pharmaceutical trademarks have a low threshold for confusion. Even a mere possibility of phonetic deception can trigger an injunction,” Jha said.
On March 27, the court ordered Dr. Reddy’s to halt sales under “Olymviq,” with the product to be rebranded as “Olymra” (see here).
"The court has made it clear that pharmaceutical trademarks are subject to a stricter anti-confusion standard compared to common consumer goods, setting a precedent that Novo can utilize to its advantage," Hanspal said.
— No to evergreening —
The expiry of Novo’s compound patent underscores the limits of so-called evergreening under Indian law.
In the run-up to March 20, the Delhi High Court repeatedly refused interim injunctions against generic challengers, including Dr. Reddy’s and Torrent. Courts were persuaded by "credible challenges" to the patent’s validity, often viewing secondary claims as obvious extensions of earlier "genus" patents.
Novo failed to meet the heightened bar under Section 3(d) of India’s Patents Act, which bars protection for incremental modifications of known drugs.
Although Novo still holds a web of secondary patents — covering devices, processes and formulations through 2031–2033 — these are already under challenge. Companies such as Natco have filed non-infringement suits targeting these layers, said Sidhant Goel, senior partner at Sim & San.
"Semaglutide is the latest reminder that secondary patents are not a guarantee of extended exclusivity," said Shwetasree Majumder, managing partner at Fidus Law Chambers.
Generic manufacturers, meanwhile, litigated aggressively to ensure day-one market entry. "Our objective from Day 1 was to commence domestic manufacturing and exports, which we have achieved," Goel said, representing Dr. Reddy’s.
Lifecycle strategies effective in the US or Europe do not translate easily to India, particularly when built on formulation or delivery patents, Majumder added.
"With patents out of the way, the battleground will shift — from patent law to regulatory enforcement, branding and market conduct," she said.
— Potential financial debt —
Beyond lost market share, Novo may face financial exposure.
If secondary patents are revoked, the company could face restitution claims from generics for being excluded from the market. "More than just a loss of future revenue, Novo could be looking at a massive potential debt," IP lawyer Aman Sinha said.
Under Indian law, patent validity is only conclusively established after surviving revocation challenges.
By relying on secondary patents seen as vulnerable, Novo may have exposed itself to damage claims. As Sinha put it, "the only thing more expensive than losing a patent is losing one you’ve used to block the competition."
Jha said that while generic companies often claim loss of opportunity, there is little precedent in the Indian pharma sector where a patentee had to pay damages to a generic. She cited the case of Merck vs. Glenmark, which shows the generic paying the innovator.
Dr. Reddy’s licensing of semaglutide in the US "weakens any argument that Novo's patent is 'frivolous' or 'invalid,'" Jha said.
Commenting on the US licensing contract, Goel said that it wasn't an admission of weakness. "In a B2B context, you often negotiate from a position of strength to cut short a long, expensive battle. Dr Reddy's US settlement is 'without prejudice' and contains no acknowledgement of the patent's validity or infringement," he added.
— China pushes innovation over imitation —
China presents a contrasting model, with stronger judicial support for pharmaceutical innovation.
In December 2025, the Supreme Court upheld Novo’s semaglutide patent, allowing supplementary experimental data to support claims.
Although the patent expired in March 2026, the ruling signals that competition will not be purely generic-led. Instead, it is expected to drive parallel innovation, with improved formulations and next-generation therapies entering the market.
Legal experts said the decision incentivizes Chinese drugmakers to pursue true "first-in-class" innovation and meaningful improvements on existing drugs, reinforcing the country’s shift from reliance on generics to innovation-driven growth.
With multiple domestic players already prepared, success will hinge on regulatory speed, manufacturing quality and the ability to turn products into real revenue.
— Firm exclusivity amid US policy pressure —
In contrast, US exclusivity remains intact despite global generic momentum.
Although the primary patent expired in March 2026, extensions linked to US Patent No. 8,129,343 run until December 2031. Additional patents tied to Ozempic extend as far as 2038.
Novo has successfully defended these assets, with the Patent Trial and Appeal Board declining to review key patents in 2023.
Critics, including I-MAK, describe this as a “patent thicket” aimed at “delaying competition and extending product profitability,” estimating potential revenues of $166 billion over the extended period.
Others argue these patents protect incremental innovations rather than blocking true generic entry.
A June 2024 US Patent and Trademark Office, or USPTO, study found no clear link between the number of patents and delayed generic entry, cautioning that raw patent counts are an unreliable measure of market exclusivity.
“Simply quantifying raw numbers of patents and exclusivities is an imprecise way to measure the intellectual property landscape of a drug product because not every patent or exclusivity has the same scope,” the office said.
Policy pressure is nonetheless rising. The US Federal Trade Commission, or FTC, flagged 17 Novo Ozempic-related patents as potentially ineligible for listing in the US Food and Drug Administration’s Orange Book of approved drugs, because they contained no active ingredient (see here). This has prompted Novo to move toward delisting 13 device-or delivery-related patents.
Meanwhile, pricing reform is underway. Under the US Inflation Reduction Act, Medicare beneficiaries will see a “71 percent discount” on Novo’s GLP-1 drugs. By January 2027, the monthly costs will stand reduced from $959 to $274.
However, the benefit is limited to about 2.3 million seniors, leaving millions of younger Americans without similar relief.
— New global playbook —
Semaglutide’s post-patent trajectory in India may become a template for other high-value drugs: weak tolerance for evergreening, rapid generic entry and an immediate shift to price competition.
As jurisdictions diverge — with India prioritizing access, China nudging innovation and the US sustaining exclusivity — the global playbook for pharmaceutical lifecycle management is being quietly rewritten.
- With additional analysis by Xiaoqiong Gao
Please email editors@mlex.com to contact the editorial staff regarding this story, or to submit the names of lawyers and advisers.